Calgary, Alberta, December 3, 2024: Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM) (OTC:HMTXF) (FSE:2VF0) is pleased to announce it is amending its closing documents to include an additional subscription of $50,000. The combined Offerings resulted
Latest news and articles!
Calgary, Alberta, November 28, 2024 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM) (OTC:HMTXF) (FSE:2VF0) is pleased to announce it has closed its second and final tranche of the private placement of units (“Units”), as
Calgary, Alberta, November 25, 2024: Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM) (OTC:HMTXF) (FSE:2VF0) is pleased to announce that, focusing on revenue, it has retained social media experts to educate and sell caregivers and individuals
Calgary, Alberta, October 31, 2024 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM) (OTC:HMTXF) (FSE:2VF0) is pleased to announce it has closed its first tranche of the private placement of units (“Units”), as announced on
Calgary, Alberta, October 11, 2024 – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce that the Company is closing up to $4,000,000 of financing in tranches from the sale of Common Shares and Units
Calgary, Alberta, August 1, 2024 – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it and CytoImmune Therapuetics (“CytoImmune”) today signed a binding and funded definitive Manufacturing Services Agreement that re-establishes production of ACP-01
Calgary, Alberta, June 11, 2024 – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by
Calgary, Alberta, June 3, 2024 – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it has signed a Letter of Intent (“LOI”) with CytoImmune Therapuetics (“CytoImmune”) to re-establish production of ACP-01 (“ACP”) in CytoImmune’s
Calgary, Alberta, March 7, 2024, 2024 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. (“OHAM”), an Exempt Market
Calgary, Alberta, February 6, 2024 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company’s Phase II randomized